First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
Article in BMC Medicine (January 2023)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Article in BMC Medicine (January 2023)
Article in Cancer and Metastasis Reviews (May 2020)
Article in Pharmacogenomics (October 2019)